Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Okey Stephanie

Knight Jeff E.

Struthers Richard Scott

Betz Stephen F.

Vivaldi Coelho Rogerio

Get Trading Activities on X and Personalized AI Stock Analysis. Not investment advice. Sign up for free at https://t.co/Szbuf7KmLT

Fintwit.ai

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Marty Chargin

Teaching traders how to trade with conviction.

Flow Education @ BullFlow https://t.co/iWqwhYLiqb
Live Trading @ Stock Talk Insiders https://t.co/8mopfzD9l9

Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Analysis & Trade Signals